News Related to Platelet-Derived Growth Factor Receptor

Related coverage linked through entity extraction aliases.

International Workshops Prioritize Drug Targets for Childhood Medulloblastoma and Rhabdoid Tumours

Jul 13, 2026

International expert workshops have identified priority therapeutic targets for medulloblastoma and rhabdoid tumours, two rare childhood cancers. For medulloblastoma, key priorities include SRC degradation, c-MYC/MYCN inhibition, and B7-H3 targeted approaches. For rhabdoid tumours, DCAF5 and MDM2 were highlighted, with EZH2 degraders showing potential.

Cogent Biosciences Prepares Up to Three FDA Filings for Bezuclastinib Following Pivotal Wins

Mar 15, 2026

Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.